Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

June 1st 2020

RET inhibitor pralsetinib induced responses in a number of patients with rare and difficult to treat RET fusion–positive solid tumors.

IASLC Survey Illustrates Current Barriers to Molecular Testing in Lung Cancer

May 28th 2020

The rate of global molecular testing is low and is limited by a number of factors, including cost, quality, turn-around time, access, and lack of awareness of testing.

Dr. Dimou on Managing Disease Progression in NSCLC

May 22nd 2020

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Dr. Dimou on Managing Disease Progression in NSCLC

May 21st 2020

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved two companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with olaparib.

Blood-Based Assay Shows Preliminary Promise as Screening Tool in Cancer Diagnostics

May 19th 2020

David D. Thiel, MD, discussed the results of a CCGA study and the next steps with this research.

FDA Approves PD-L1 IHC 28-8 pharmDx as Companion Diagnostic for Nivolumab Plus Ipilimumab in NSCLC

May 18th 2020

The FDA has approved PD-L1 IHC 28-8 pharmDx for use as a companion diagnostic to identify patients with metastatic non–small cell lung cancer with PD-L1 tumor expression ≥1%, making them eligible for frontline treatment with nivolumab plus ipilimumab.

Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

May 18th 2020

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Larotrectinib Benefits Patients With NTRK Fusions, Regardless of Pretreatment or Performance Status

May 11th 2020

David S. Hong, MD, discusses the results of these analyses with larotrectinib in patients with NTRK alterations.

FDA Approves myChoice CDx as Companion Diagnostic for Olaparib in Ovarian Cancer

May 11th 2020

The FDA has approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with positive homologous recombination deficiency status, making them eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.

FDA Approves myChoice CDx as Companion Diagnostic for Olaparib in Ovarian Cancer

May 11th 2020

Oncology Clinical Trials Should Reflect Molecular Advances, Real-World Patients

May 11th 2020

From the earliest moments of medical school instruction, through residency and fellowship training, physicians are taught the primacy of the randomized phase 3 trial in the hierarchy of evidence-based medicine.

Dr. Hughes on Mutational Risk in Oncology

May 9th 2020

Kevin Hughes, MD, discusses mutational risk in oncology.

Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant Tumors

May 8th 2020

Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

May 5th 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Defactinib Plus RAF/MEK Inhibitor Combo Active in KRAS-Driven Cancers

May 5th 2020

Udai Banerji, discusses the rationale for a phase 1 trial, the potential implications of these data, and future studies in development.

Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

May 5th 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Despite Advances, Genetic Testing Remains Underutilized in Breast Cancer

April 30th 2020

Kevin Hughes, MD, highlights the need for widespread implementation of genetic testing in breast cancer.

Blood Test Is Feasible for Early Detection Across Multiple Cancers

April 29th 2020

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.

Larotrectinib Approved in UK for NTRK+ Cancers

April 22nd 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended larotrectinib for the treatment of adult and pediatric patients with advanced NTRK fusion–positive solid tumors.